Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Public ClinicalTrials.gov record NCT02289898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Study identification
- NCT ID
- NCT02289898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2015 (Actual)
- Primary completion
- May 2017 (Actual)
- Completion
- Sep 2017 (Actual)
- Last update posted
- Sep 28, 2020
2015 – 2017
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Providence Saint Joseph Medical Center | Burbank | California | 91505 | — |
| City of Hope | Duarte | California | 91010 | — |
| Scripps Cancer Center | La Jolla | California | 92037 | — |
| University of California, Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Soulhern California Permanente Medical Group | San Marcos | California | 92078 | — |
| Kaiser Permanente Medical Center | Vallejo | California | 94589 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Kaiser Permanente NW Oncology Research | Portland | Oregon | 97227 | — |
| Thomas Jefferson University, Sydney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Research Treatment Center | Lubbock | Texas | 79410 | — |
| Huntsman Cancer Institute at The University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02289898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2020 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02289898 live on ClinicalTrials.gov.